These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 28714525)

  • 1. Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study.
    Kern A; Gil RJ; Bojko K; Rzeszowski B; Bednarski K; Górny J; Bil J
    Cardiol J; 2018; 25(2):188-195. PubMed ID: 28714525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studies.
    Gil RJ; Bil J; Kern A; Iñigo Garcia LA; Formuszewicz R; Dobrzycki S; Vassilev D; Segiet A
    Cardiol J; 2018; 25(3):308-316. PubMed ID: 28840591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The approach to coronary bifurcation treatment and its outcomes in Poland: The single center experience.
    Kern A; Gil RJ; Bojko K; Rzeszowski B; Jalali R; Górny J; Bil J
    Cardiol J; 2017; 24(6):589-596. PubMed ID: 28541601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial.
    Gil RJ; Bil J; Džavík V; Vassilev D; Kern A; Formuszewicz R; Zalewska-Adamiec M; Dobrzycki S
    Can J Cardiol; 2015 May; 31(5):671-8. PubMed ID: 25828372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial.
    Gil RJ; Bil J; Grundeken MJ; Kern A; Iñigo Garcia LA; Vassilev D; Pawłowski T; Formuszewicz R; Dobrzycki S; Wykrzykowska JJ; Serruys PW
    EuroIntervention; 2016 Dec; 12(11):e1404-e1412. PubMed ID: 26600564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® - three-month results.
    Gil RJ; Bil J; Kern A; Pawłowski T
    Kardiol Pol; 2018; 76(2):464-470. PubMed ID: 29192951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dedicated bifurcation paclitaxel-eluting stent BiOSS Expert® in the treatment of distal left main stem stenosis.
    Bil J; Gil RJ; Vassilev D; Rzezak J; Kulawik T; Pawlowski T
    J Interv Cardiol; 2014 Jun; 27(3):242-51. PubMed ID: 24708143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-man study of paclitaxel-eluting stent BiOSS (Bifurcation Optimisation Stent System) dedicated for coronary bifurcation stenoses: three months results.
    Gil RJ; Vassiliev D; Michałek A; Kern A; Formuszewicz R; Dobrzycki S; Lesiak M; Wójcik J; Kardaszewicz P; Lekston A
    Kardiol Pol; 2012; 70(1):45-52. PubMed ID: 22267425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-man study of dedicated bifurcation sirolimus-eluting stent: 12-month results of BiOSS LIM® Registry.
    Gil RJ; Bil J; Vassiliev D; Iñigo Garcia LA
    J Interv Cardiol; 2015 Feb; 28(1):51-60. PubMed ID: 25689548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry.
    Gil RJ; Bil J; Grundeken MJ; Iñigo Garcia LA; Vassilev D; Kern A; Pawłowski T; Wykrzykowska JJ; Serruys PW
    EuroIntervention; 2016 Nov; 12(10):1246-1254. PubMed ID: 26465375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of a dedicated bifurcation stent system.
    Sivalingam J; Mazhar MW; Chaddad RA; Fouladvand F; Cortese B
    Cardiovasc Revasc Med; 2024 Feb; 59():21-26. PubMed ID: 37666716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies.
    Gil RJ; Bil J; Kern A; Iñigo-Garcia LA; Formuszewicz R; Dobrzycki S; Vassilev D; Mehran R
    Cardiovasc Ther; 2020; 2020():6760205. PubMed ID: 32411301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Outcomes of Different Two-Stent Techniques With Second-Generation Drug-Eluting Stents for Unprotected Left Main Bifurcation Disease: Insights From the FAILS-2 Study.
    Pavani M; Conrotto F; Cerrato E; D'Ascenzo F; Kawamoto H; Núñez-Gil IJ; Pennone M; Garbo R; Tomassini F; Colombo F; Scacciatella P; Varbella F; Chieffo A; Colombo A; Escaned J
    J Invasive Cardiol; 2018 Aug; 30(8):276-281. PubMed ID: 30068784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healing responses after bifurcation stenting with the dedicated TRYTON Side-Branch Stent™ in combination with XIENCE-V™ stents: a clinical, angiography, fractional flow reserve, and optical coherence tomography study: the PYTON (Prospective evaluation of the TRYTON Side-Branch Stent™ with an additional XIENCE-v™ everolimus-eluting stent in coronary bifurcation lesions) study.
    Dubois C; Adriaenssens T; Ughi G; Wiyono S; Bennett J; Coosemans M; Ferdinande B; Sinnaeve P; D'hooge J; Desmet W
    Catheter Cardiovasc Interv; 2013 Feb; 81(3):E155-64. PubMed ID: 22745031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiographic study of the clinical liaison of drug-eluting stent and paclitaxel-eluting balloon in unifocal side branch ostium stenosis (ASCLEPIUS).
    Jim MH; Wu EB; Chan CY; Wong KL; Fung RC; Yiu KH
    Heart Vessels; 2017 Sep; 32(9):1045-1050. PubMed ID: 28357514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 12-month intravascular ultrasound observations from BiOSS® first-in-man studies.
    Gil RJ; Bil J; Costa RA; Gil KE; Vassiliev D
    Int J Cardiovasc Imaging; 2016 Sep; 32(9):1339-1347. PubMed ID: 27314841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results.
    Gil RJ; Kern A; Bojko K; Gziut-Rudkowska A; Vassilev D; Bil J
    Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.
    Kervinen K; Niemelä M; Romppanen H; Erglis A; Kumsars I; Maeng M; Holm NR; Lassen JF; Gunnes P; Stavnes S; Jensen JS; Galløe A; Narbute I; Sondore D; Christiansen EH; Ravkilde J; Steigen TK; Mannsverk J; Thayssen P; Hansen KN; Helqvist S; Vikman S; Wiseth R; Aarøe J; Jokelainen J; Thuesen L;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1160-5. PubMed ID: 24262616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-year results of BiOSS stents in coronary bifurcation treatment.
    Gil RJ; Kern A; Formuszewicz R; Iñigo Garcia LA; Dobrzycki S; Vassilev D; Bil J
    Eur J Clin Invest; 2021 Aug; 51(8):e13555. PubMed ID: 33782985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.